1. US Food and Drug Administration. FDA updates and press announcements on NDMA in zantac (ranitidine). 30 October 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine. Accessed 22 June 2020.
2. US Food and Drug Administration. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine. 13 September 2019. https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine. Accessed 22 Jun 2020.
3. European Medicines Agency. EMA to review ranitidine medicines following detection of NDMA. 13 September 2019. https://www.ema.europa.eu/en/documents/press-release/ema-review-ranitidine-medicines-following-detection-ndma_en.pdf. Accessed 22 June 2020.
4. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1–42. Lyon; 1987: Suppl. 7. https://publications.iarc.fr/Book-And-Report-Series/Iarc-Monographs-Supplements/Overall-Evaluations-Of-Carcinogenicity-An-Updating-Of-IARC-Monographs-Volumes-1%E2%80%9342-1987
5. Ministry of Health, Labour and Welfare. Response to the detection of carcinogens in ranitidine hydrochloride (in Japanese). 29 October 2019. https://www.mhlw.go.jp/content/11120000/000560996.pdf. Accessed 22 June 2020.